Danuglipron tromethamine is under clinical development by Pfizer and currently in Phase I for Renal Failure. According to GlobalData, Phase I drugs for Renal Failure have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Danuglipron tromethamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Danuglipron tromethamine overview
Danuglipron (PF-06882961) is under development for the treatment of type 2 diabetes, renal impairment and obesity. The drug candidate is a new molecular entity. It is a small molecule administered orally as an immediate or controlled release solution or tablet. It acts by targeting glucagon-like peptide1 receptor. It was also under development for the treatment of non-alcoholic steatohepatitis.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Danuglipron tromethamine’s drug-specific PTSR and LoA scores, buy the report here.